First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

已完结 20 由 Aixuexi 发布于 2026/9/15 15:46:14

DOI:10.1158/1078-0432.ccr-25-4485
作者：Jhanelle E. Gray, Joel W. Neal, Jyoti D. Patel, Stephen V. Liu, Rémi Veillon, Martin Reck, Federico Cappuzzo, Manuel Cobo, Noemí Reguart, José Fuentes Pradera, Byoung Chul Cho, Tony Mok, Sabeen Mek
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：Purpose: EVOKE-02 (NCT05186974) is a multicohort, phase II trial evaluating first-line sacituzumab govitecan (SG) plus pembrolizumab with or without platinum-based chemotherapy in patients w

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Numerical Simulation Analysis on Production Evolution Laws in Shale Reservoirs Considering a Horizontal Well Interwell Interference Effect